Siemens Healthineers has been given a 'Neutral' rating by UBS, with a target price of 53 euros.
Analyst Graham Doyle has highlighted the company's progress in photon-counting computed tomography (PCCT), noting that they have expanded their product pipeline from one to three devices. This expansion allows Siemens Healthineers to cater to a wider range of target groups and budgets. The report, published on December 2, 2024, emphasizes the strategic advancements made by the company in the medical technology sector.
The ability to offer multiple devices enhances Siemens Healthineers' competitive position in the market, positioning them well for future growth.